PMID- 32783974
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 161
DP  - 2020 Nov
TI  - Biological therapy in pediatric age.
PG  - 105120
LID - S1043-6618(20)31428-6 [pii]
LID - 10.1016/j.phrs.2020.105120 [doi]
AB  - Biological therapies, especially blocking tumor necrosis factor-alpha (TNFalpha) agents 
      have radically changed the therapeutic approach and disease course of pediatric 
      inflammatory bowel disease (IBD). In particular, drugs such as infliximab (IFX) 
      and adalimumab (ADA) have been demonstrated to be effective in inducing and 
      maintaining corticosteroid-free remission in both adult and pediatric patients 
      with Crohns Disease (CD) and Ulcerative colitis (UC). Biosimilar biological 
      (BioS) therapy is increasingly being used in pediatric age even though most 
      knowledge on the safety and efficacy of these agents is based on IFX in adult IBD 
      data. Studies show high rates of clinical response and remission in both IFX 
      naive patients and in patients switched from originator to BioS with similar 
      risks of adverse events (AEs) as those reported with IFX originator. In the 
      present review indications, efficacy and AEs of biological therapy in pediatric 
      IBD will be discussed, as well as the role of other biological agents such as 
      Golimumab, Vedolizumab and Ustekinumab, the role of BioS biological therapy and 
      utility of therapeutic drug monitoring in clinical practice.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Penagini, Francesca
AU  - Penagini F
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      francesca.penagini@asst-fbf-sacco.it.
FAU - Cococcioni, Lucia
AU  - Cococcioni L
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      lucia.cococcioni@asst-fbf-sacco.it.
FAU - Pozzi, Elena
AU  - Pozzi E
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      elena.pozzi@asst-fbf-sacco.it.
FAU - Dilillo, Dario
AU  - Dilillo D
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      dario.dilillo@asst-fbf-sacco.it.
FAU - Rendo, Giulia
AU  - Rendo G
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      giulia.rendo@unimi.it.
FAU - Mantegazza, Cecilia
AU  - Mantegazza C
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      cecilia.mantegazza@asst-fbf-sacco.it.
FAU - Zuccotti, Gian Vincenzo
AU  - Zuccotti GV
AD  - Pediatric Department, University of Milan, "V. Buzzi" Children's Hospital, ASST 
      FBF SACCO, via Castelvetro 32, 20154 Milan, Italy. Electronic address: 
      gianvincenzo.zuccotti@unimi.it.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200809
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Biological Products)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - Pediatric Crohn's disease
RN  - Pediatric ulcerative colitis
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Biological Products/adverse effects/*therapeutic use
MH  - Biosimilar Pharmaceuticals/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Colitis, Ulcerative/diagnosis/*drug therapy/immunology
MH  - Crohn Disease/diagnosis/*drug therapy/immunology
MH  - Drug Monitoring
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Infant
MH  - Male
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Inhibitors/adverse effects/*therapeutic use
OTO - NOTNLM
OT  - Adalimumab
OT  - Anti-Tnfalpha agents
OT  - Biosimilar biological therapy
OT  - Inflammatory bowel disease
OT  - Infliximab
OT  - Pediatrics
EDAT- 2020/08/14 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/07/30 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - S1043-6618(20)31428-6 [pii]
AID - 10.1016/j.phrs.2020.105120 [doi]
PST - ppublish
SO  - Pharmacol Res. 2020 Nov;161:105120. doi: 10.1016/j.phrs.2020.105120. Epub 2020 
      Aug 9.